Appointments

A potential therapeutic target for kidney cancers that have a common genetic change has been discovered by scientists at the University of North Carolina...

Novartis has gained new approval for Kisqali in the US for women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or...

Sanofi and Revolution Medicines have partnered to develop and commercialise targeted therapies, based on the biology of the cellular enzyme SHP2, for patients with...